Login to Your Account



Pluristem Raising $32M Publicly As PLX Pipeline Gains Attention

By Jennifer Boggs
Managing Editor

Wednesday, September 19, 2012
Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription